Sunesis Pharmaceuticals Inc. (SNSS): Take a look on insiders transactions

Oppenheimer announced it was Downgrade coverage of Sunesis Pharmaceuticals Inc. in a research note on June 24, 2020. The analysts assigned a Perform rating to the stock. Wells Fargo rated the stock as a Equal weight in a research noted published on March 11, 2020. H.C. Wainwright rated the stock as a Neutral in a research note published on December 20, 2018.

Gullotta Tina, the VP, Finance of Sunesis Pharmaceuticals Inc., bought 6000.0 shares at the valuation of $0.33 during an exchange that occurred on May 29, which implies that Gullotta Tina is holding 20,500 shares at the estimation of $1,989 dependent on the most recent closing price.

In another transaction, on Nov 29, See Remarks of Sunesis Pharmaceuticals Inc., Quinn William P., bought 6000.0 shares at the price of $0.37. After this activity, Quinn William P. now keeps 127,697 shares of Sunesis Pharmaceuticals Inc., esteemed at $2,193 with the most recent shutting price.

SNSS Recent Trade

The share price of SNSS descended by -$0.01 during the exchanging session on 07/28/20 to exchange at $0.40. Sunesis Pharmaceuticals Inc. stock has an exchanging volume of 21.24 million shares, which is high, contrasted with its 3-months average volume of 6.24M shares. Its market capitalization has now reached to $42.27M.

SNSS Past Trading Activity

The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, SNSS price has rose by 3.32%. In the course of past three months sees the stock go down around -12.86%, while it has lost -21.81% over the past six months and 17.18% since the start of the year.

SNSS Earning History

Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Jun 2020), the firm recorded a revenue of 120.0 million, which was higher than the gauge of 190k made by certain experts. For that equivalent quarter, Sunesis Pharmaceuticals Inc. posted -$0.05 earnings per share (EPS) which was above the consensus estimate of -$0.07 by $0.02, which represents to an expansion by 28.60%.

SNSS Price Performance

Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Sunesis Pharmaceuticals Inc. has seen its stock exchanging -43.39% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +58.41% above its three-month low. A more extensive look sees SNSS exchanging -64.98% beneath its 52-week high and 102.82% above from its 52-week low price.

SNSS Instability & Beta Factor

The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 20.69%, while it has a month to month instability of 13.72%. The company has an ATR (Average True Range) of 0.06 and a beta factor of 1.90.

Leave a Comment